[go: up one dir, main page]

BR9712978A - Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada - Google Patents

Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada

Info

Publication number
BR9712978A
BR9712978A BR9712978-0A BR9712978A BR9712978A BR 9712978 A BR9712978 A BR 9712978A BR 9712978 A BR9712978 A BR 9712978A BR 9712978 A BR9712978 A BR 9712978A
Authority
BR
Brazil
Prior art keywords
gene
mammalian
cell
virus
altered
Prior art date
Application number
BR9712978-0A
Other languages
English (en)
Inventor
Frederick M Boyce
James G Barsoum
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of BR9712978A publication Critical patent/BR9712978A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"VìRUS DE DNA DE NãO-MAMìFEROS POSSUINDO UMA PROTEìNA DE REVESTIMENTO ALTERADA"<D>. São divulgados processos, ácidos nucléicos e células para expressar um gene exógeno em uma célula de mamífero, envolvendo a introdução na célula de um DNA de vírus de não mamífero (por exemplo, um baculovírus) que tem uma capa alterada de proteína, o genoma de cujo vírus contém um gene exógne e cultivando a célula sob condições tais que o gene seja expresso. São também divulgados processos para tratamento de perturbações de deficiência de gene, perturbações neurológicas ou cânceres em um mamífero (1) fornecendo a uma célula uma quantidade terapeuticamente eficaz de um DNA de vírus de não mamífero que tem uma capa alterada de proteína, o genoma de cujo vírus contém um gene exógeno, terapêutico e (2) cultivando a célula sob condições tais que o gene seja expresso no mamífero.
BR9712978-0A 1996-09-11 1997-09-11 Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada BR9712978A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2629796P 1996-09-11 1996-09-11
PCT/US1997/016041 WO1998011243A2 (en) 1996-09-11 1997-09-11 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein

Publications (1)

Publication Number Publication Date
BR9712978A true BR9712978A (pt) 2000-04-18

Family

ID=21831009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712978-0A BR9712978A (pt) 1996-09-11 1997-09-11 Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada

Country Status (9)

Country Link
US (2) US6338953B1 (pt)
EP (1) EP0931159A2 (pt)
JP (1) JP2001508645A (pt)
KR (1) KR20000036051A (pt)
AU (1) AU4340397A (pt)
BR (1) BR9712978A (pt)
CA (1) CA2264966A1 (pt)
IL (1) IL128769A0 (pt)
WO (1) WO1998011243A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
GB9708698D0 (en) * 1997-04-29 1997-06-18 Imperial College Materials for therapy
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU2006225325B2 (en) * 1997-12-22 2010-04-22 The University Of Tennessee Research Corporation Recombinant Rhabdovirus containing a heterologous fusion protein
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
FR2781503B1 (fr) * 1998-07-24 2003-01-31 Rhone Poulenc Rorer Sa Nouveaux vecteurs derives de baculovirus et utilisation pour le transfert d'acides nucleiques dans les cellules nerveuses
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
JP2003527816A (ja) * 1998-07-24 2003-09-24 アバンテイス・フアルマ・エス・アー バキュロウイルス由来のベクター及び脊椎動物の神経細胞に核酸を導入するための該ベクターの使用
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
AU8330401A (en) * 2000-08-11 2002-02-25 Favrille Inc Method and composition for altering a t cell mediated pathology
WO2002014527A2 (en) * 2000-08-11 2002-02-21 Boyce Thompson Institute For Plant Research, Inc. Gp64-null baculoviruses pseudotyped with heterologous envelope proteins
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002085287A2 (en) * 2001-04-18 2002-10-31 Genstar Therapeutics Corp. Minimal adenoviral vectors for immunization
EP1395293B1 (en) * 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
GB0119852D0 (en) * 2001-08-15 2001-10-10 Univ York Baculovirus
US6863884B2 (en) * 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
EP1548119A4 (en) * 2002-09-25 2006-08-02 Osaka Ind Promotion Org BACULAR VIRUS VECTOR, METHOD OF CONSTRUCTING THE BACULAR VIRUS VECTOR AND GENTRANSFER METHOD
PL1606409T3 (pl) * 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US20080044855A1 (en) * 2006-03-22 2008-02-21 Yan Xu System for regulated and enhanced baculovirus mediated transient transgene expression in mammalian cells
WO2007149946A2 (en) * 2006-06-20 2007-12-27 Invitrogen Corporation Composition and methods for expressing reporter molecules in mammalian cells
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
EP2217697B1 (en) * 2007-11-08 2015-06-10 Biogen MA Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
WO2010005570A2 (en) * 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
US20150197773A1 (en) * 2012-04-10 2015-07-16 Agency For Science, Technology And Research Methods for bladder cancer therapy using baculoviral vectors
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
HK1246810A1 (zh) 2015-01-08 2018-09-14 Biogen Ma Inc. Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2020068862A1 (en) * 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
EP4472644A2 (en) * 2022-02-02 2024-12-11 FibroBiologics, Inc. Therapeutic use of fibroblasts to stimulate the immune system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
FR2579224B1 (fr) 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine
US5004687A (en) 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
US5106741A (en) 1985-12-20 1992-04-21 The Upjohn Company Tissue plasminogen activator (TPA) analogs
US5476781A (en) 1991-02-19 1995-12-19 University Of Florida Research Foundation, Inc. Entomopoxvirus spheroidin gene sequences
WO1992014829A1 (en) * 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
DE4407859C1 (de) 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CA2200835A1 (en) * 1994-09-23 1996-03-28 Frederick M. Boyce Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
CA2264966A1 (en) 1998-03-19
US6338953B1 (en) 2002-01-15
IL128769A0 (en) 2000-01-31
KR20000036051A (ko) 2000-06-26
JP2001508645A (ja) 2001-07-03
EP0931159A2 (en) 1999-07-28
US6190887B1 (en) 2001-02-20
WO1998011243A3 (en) 1998-05-07
WO1998011243A9 (en) 2001-06-21
WO1998011243A2 (en) 1998-03-19
AU4340397A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
BR9712978A (pt) Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada
WO1998012311A3 (en) Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
Dianov et al. Base excision repair in nuclear and mitochondrial DNA
Li et al. Synergistic function of DNA methyltransferases Dnmt3a and Dnmt3b in the methylation of Oct4 and Nanog
Yacoub et al. A Drosophila ribosomal protein contains 8‐oxoguanine and abasic site DNA repair activities.
WO2000077233A3 (en) Complement-resistant non-mammalian dna viruses and uses thereof
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
ATE313642T1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
IL193758A0 (en) Genetically engineered duckweed
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
BR9802542A (pt) Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios.
CY1108240T1 (el) ΑΠΟΜΟΝΩΜΕΝΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΤΑ ΟΠΟΙΑ ΕΧΟΥΝ ΕΝΑ ΜΕΙΩΜΕΝΟ ΠΕΡΙΕΧΟΜΕΝΟ ΜΟΤΙΒΩΝ 5΄CpG3΄ ΕΠΙΓΕΝΕΤΙΚΟΥ ΕΛΕΓΧΟΥ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΟΥΣ
CA2281895A1 (en) Ikb kinases
FI925210A0 (fi) Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5&#39;-aenda
Kim et al. Purification and characterization of UV endonucleases I and II from murine plasmacytoma cells
Browne et al. The sequence specificity of a mammalian DNA methylase
Pfeifer et al. Mouse DNA‐cytosine‐5‐methyltransferase: sequence specificity of the methylation reaction and electron microscopy of enzyme‐DNA complexes.
Helland et al. Properties and mechanism of action of eukaryotic 3-methyladenine-DNA glycosylases
US20250277256A1 (en) Nucleic acid detection and analysis systems
DE69734555D1 (de) Unsterbliche retinalzellinien und deren anwendungen
Hovanessian et al. Protein kinase in human plasma analogous to that present in control and interferon-treated HeLa cells
Nakanishi et al. Characterization of three proteins stimulating RNA polymerase II
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
Paoletti et al. The mitochondrial DNA of malignant cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1903 DE 26/06/2007.